HK1163250A1 - Methods and marker combinations for screening for predisposition to lung cancer - Google Patents

Methods and marker combinations for screening for predisposition to lung cancer

Info

Publication number
HK1163250A1
HK1163250A1 HK12103730.5A HK12103730A HK1163250A1 HK 1163250 A1 HK1163250 A1 HK 1163250A1 HK 12103730 A HK12103730 A HK 12103730A HK 1163250 A1 HK1163250 A1 HK 1163250A1
Authority
HK
Hong Kong
Prior art keywords
predisposition
screening
methods
lung cancer
marker combinations
Prior art date
Application number
HK12103730.5A
Other languages
English (en)
Chinese (zh)
Inventor
Tracey Colpitis
Eric L Russel
Stephen Frost
Javier Ramirez
Bhawani Singh
John C Russel
Original Assignee
Abbott Molecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Molecular Inc filed Critical Abbott Molecular Inc
Publication of HK1163250A1 publication Critical patent/HK1163250A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK12103730.5A 2007-06-29 2012-04-16 Methods and marker combinations for screening for predisposition to lung cancer HK1163250A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/771,727 US9347945B2 (en) 2005-12-22 2007-06-29 Methods and marker combinations for screening for predisposition to lung cancer

Publications (1)

Publication Number Publication Date
HK1163250A1 true HK1163250A1 (en) 2012-09-07

Family

ID=40226787

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12103730.5A HK1163250A1 (en) 2007-06-29 2012-04-16 Methods and marker combinations for screening for predisposition to lung cancer

Country Status (7)

Country Link
US (4) US9347945B2 (ja)
EP (4) EP3270164A1 (ja)
JP (3) JP5611821B2 (ja)
CA (2) CA2691852C (ja)
ES (3) ES2596807T3 (ja)
HK (1) HK1163250A1 (ja)
WO (1) WO2009006323A2 (ja)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2610806T3 (es) * 2005-12-22 2017-05-03 Abbott Molecular Inc. Métodos y combinaciones de marcadores para la detección de la predisposición al cáncer de pulmón
US9347945B2 (en) * 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20080133141A1 (en) * 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
EP3115469B1 (en) * 2007-11-19 2020-04-29 Celera Corporation Lung cancer markers and uses thereof
ES2703714T3 (es) 2009-03-12 2019-03-12 Cancer Prevention & Cure Ltd Métodos de identificación, evaluación, prevención y terapia de enfermedades pulmonares y kits de los mismos, incluida la identificación, evaluación, prevención y terapia de enfermedades en base al género
CA2761873A1 (en) * 2009-05-15 2010-11-18 F. Hoffmann-La Roche Ag Cybp as a marker for lung cancer
ES2361808B8 (es) * 2009-05-25 2012-11-29 Consejo Superior De Investigaciones Cientificas (Csic) 20% Método de obtención de datos útiles para el diagnóstico o el pronóstico del cáncer colorrectal.
EP2567232A1 (en) * 2010-05-07 2013-03-13 AbbVie Inc. Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2012054732A2 (en) * 2010-10-20 2012-04-26 Rush University Medical Center Lung cancer tests
KR101708651B1 (ko) * 2010-12-31 2017-03-08 (주) 프로탄바이오 혈청 아밀로이드 ａ에 대한 단일클론항체 및 이를 생산하는 하이브리도마 세포
AU2012249288C1 (en) 2011-04-29 2017-12-21 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
US8697368B2 (en) 2011-06-29 2014-04-15 Paichai University-Academic Cooperation Foundation Diagnostic marker for lung cancer comprising HPαR as active ingredient
CA2799163A1 (en) * 2011-12-18 2013-06-18 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
WO2013154998A1 (en) * 2012-04-09 2013-10-17 Duke University Serum biomarkers and pulmonary nodule size for the early detection of lung cancer
CN103163303B (zh) * 2012-06-19 2016-02-24 中国医学科学院肿瘤医院 辅助诊断肺腺癌患者的试剂盒
CN103163293B (zh) * 2012-06-19 2015-05-13 中国医学科学院肿瘤医院 辅助诊断非小细胞肺癌患者的试剂盒
CN103175969B (zh) * 2012-06-19 2015-09-02 中国医学科学院肿瘤医院 辅助诊断肺鳞癌患者的试剂盒
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
WO2014190450A1 (zh) * 2013-05-28 2014-12-04 中国医学科学院肿瘤医院 辅助诊断肺鳞癌患者的试剂盒
US11031105B2 (en) * 2013-11-07 2021-06-08 Medial Research Ltd. Methods and systems of evaluating a risk of lung cancer
WO2015088947A1 (en) * 2013-12-09 2015-06-18 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
US20160130656A1 (en) 2014-07-14 2016-05-12 Allegro Diagnostics Corp. Methods for evaluating lung cancer status
WO2016013400A1 (ja) * 2014-07-24 2016-01-28 国立大学法人 長崎大学 肺癌診断用バイオマーカー
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
WO2016094330A2 (en) * 2014-12-08 2016-06-16 20/20 Genesystems, Inc Methods and machine learning systems for predicting the liklihood or risk of having cancer
US20210072255A1 (en) 2016-12-16 2021-03-11 The Brigham And Women's Hospital, Inc. System and method for protein corona sensor array for early detection of diseases
EP3607089A4 (en) 2017-04-04 2020-12-30 Lung Cancer Proteomics, LLC PLASMA-BASED PROTEIN PROFILING FOR EARLY PROGNOSIS OF LUNG CANCER
JP7181230B2 (ja) 2017-05-31 2022-11-30 コーニンクレッカ フィリップス エヌ ヴェ 臨床判断支援のための生医療画像データの機械学習
US10340031B2 (en) * 2017-06-13 2019-07-02 Bostongene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
KR102594366B1 (ko) 2018-11-07 2023-10-27 시어 인코퍼레이티드 단백질 코로나 분석을 위한 조성물, 방법 및 시스템 및 그것들의 용도
CA3146525A1 (en) 2019-08-05 2021-02-11 William Manning Systems and methods for sample preparation, data generation, and protein corona analysis
AU2020407062A1 (en) * 2019-12-16 2022-08-04 TrialMatch.me, Inc. d/b/a Trialjectory Unsupervised taxonomy extraction from medical clinical trials
CN111175505B (zh) * 2020-01-08 2021-11-19 浙江省肿瘤医院 一种p53自身抗体检测试剂盒及其应用
AU2021269051A1 (en) * 2020-05-08 2022-11-24 The Regents Of The University Of California Apparatus and methods for pulmonary monitoring
CN116034273A (zh) * 2020-09-09 2023-04-28 株式会社日立高新技术 利用代谢物面板的癌症检查法
CN114686461B (zh) * 2022-04-08 2023-07-18 南阳理工学院 去泛素化酶usp45在制备治疗肺鳞癌药物中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB510943A (en) * 1938-12-08 1939-08-11 John Handley Improvements in and relating to indicators
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
AU4024593A (en) * 1992-04-14 1993-11-18 Abbott Laboratories Method of detecting tumors containing complexes of P53 and HSP70
US5792664A (en) 1992-05-29 1998-08-11 The Rockefeller University Methods for producing and analyzing biopolymer ladders
CA2136717A1 (en) 1992-05-29 1993-12-09 Brian T. Chait Method and product for the sequence determination of peptides using a mass spectrometer
CA2089212C (en) * 1992-06-12 2004-01-20 Ken Yamaguchi Antibodies to human gastrin-releasing peptide precusor and use thereof
PT700521E (pt) 1993-05-28 2003-10-31 Baylor College Medicine Metodo e espectrometro de massa para dessorcao e ionizacao de analitos
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
WO1999004244A1 (en) 1997-07-17 1999-01-28 Accumed International, Inc. Inspection system with specimen preprocessing
US5973119A (en) 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
AU3326000A (en) 1999-03-26 2000-10-16 George Hosokawa Means of early examination of malignant tumor
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
KR20030094281A (ko) 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
US20030003454A1 (en) * 2001-03-23 2003-01-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
JP3691798B2 (ja) 2002-02-18 2005-09-07 三洋化成工業株式会社 血液中の腫瘍マーカー定量方法
WO2003080640A1 (en) 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Lymphatic and blood endothelial cell genes
US20030198316A1 (en) 2002-04-17 2003-10-23 Piet Dewaele Osteoporosis screening method
AU2003294377A1 (en) 2002-12-18 2004-07-29 Ciphergen Biosystems, Inc. Serum biomarkers in lung cancer
AU2004227018A1 (en) 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
GB2404981A (en) 2003-08-15 2005-02-16 Univ Geneve Diagnostic method for stroke
ATE496142T1 (de) 2004-03-23 2011-02-15 Oncotherapy Science Inc Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs
WO2005098445A2 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
EP1745801A1 (en) * 2004-05-13 2007-01-24 Daiichi Pharmaceutical Co., Ltd. Method of inhibiting telomerase activity and inhibitor
WO2006005065A2 (en) 2004-06-30 2006-01-12 University Of South Florida Luminescence characterization of quantum dots conjugated with biomarkers for early cancer detection
JP2008506123A (ja) 2004-07-09 2008-02-28 トリパス イメージング， インコーポレイテッド 卵巣癌の検出のための方法および組成物
BRPI0518734A2 (pt) * 2004-11-30 2008-12-02 Veridex Llc prognàstico de cÂncer de pulmço
ES2528382T3 (es) 2005-02-18 2015-02-09 Abbott Laboratories Métodos y sondas para detectar cáncer de esófago
WO2007086915A2 (en) 2005-05-12 2007-08-02 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
ES2610806T3 (es) 2005-12-22 2017-05-03 Abbott Molecular Inc. Métodos y combinaciones de marcadores para la detección de la predisposición al cáncer de pulmón
US9347945B2 (en) * 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer

Also Published As

Publication number Publication date
EP3270164A1 (en) 2018-01-17
WO2009006323A3 (en) 2009-03-05
JP2010532480A (ja) 2010-10-07
JP6030101B2 (ja) 2016-11-24
ES2633596T3 (es) 2017-09-22
JP2015007645A (ja) 2015-01-15
US20120071334A1 (en) 2012-03-22
EP2392925B1 (en) 2015-01-14
ES2533832T3 (es) 2015-04-15
US20160320393A1 (en) 2016-11-03
EP2171464A2 (en) 2010-04-07
US20150168412A1 (en) 2015-06-18
JP5611821B2 (ja) 2014-10-22
WO2009006323A2 (en) 2009-01-08
CA2995531A1 (en) 2009-01-08
CA2691852A1 (en) 2009-01-08
EP2650683A1 (en) 2013-10-16
ES2596807T3 (es) 2017-01-12
CA2691852C (en) 2018-02-20
EP2650683B1 (en) 2017-05-31
EP2392925A1 (en) 2011-12-07
US20080160546A1 (en) 2008-07-03
EP2171464A4 (en) 2010-08-04
JP2017049263A (ja) 2017-03-09
US9347945B2 (en) 2016-05-24
EP2171464B1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
HK1163250A1 (en) Methods and marker combinations for screening for predisposition to lung cancer
EP1969363A4 (en) METHOD AND MARKER COMBINATIONS FOR SCREENING TO A LUNG CANCER INSTRUCTION
HK1204062A1 (en) Lung cancer biomarkers and uses thereof
EP2227556A4 (en) LUNG CANCER MARKERS AND THEIR USES
GB2468006B (en) Screening
GB0625321D0 (en) Cancer biomarker
EP2079385A4 (en) MAMMARY MARKER
EP2137223A4 (en) COMPOSITE MAILLARD-RESOLE BINDERS
ZA200903696B (en) Graded drilling cutters
GB0717101D0 (en) Tumour marker
PL2176664T3 (pl) Ccr4 jako marker nowotworowy
GB0724412D0 (en) Marker
TWI370107B (en) Novel methods for making and using halosilylgermanes
GB0721605D0 (en) Prostrate cancer susceptibility screening
AU320441S (en) Marker
GB0701202D0 (en) Data analysis
EP2196564A4 (en) ISOTOPIC DIAMOND LAMINATE
HK1160218A1 (en) Asc as a marker for lung cancer asc
PL2205793T3 (pl) Pokrycie toru
EP2187216A4 (en) NEW LIVER CANCER MARKER
GB0815935D0 (en) Marker apparatus
GB0717319D0 (en) Photoluminescent marker
GB0705069D0 (en) Rhizome viability determination method
GB0722156D0 (en) Braking arrangements and methods
GB0701818D0 (en) Prognostic marker for cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190625